FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327603911> ?p ?o ?g. }

• W4327603911 abstract "Many randomized controlled trials have indicated that immuno-chemotherapy could generate clinical benefits, though the cost of immuno-chemotherapy was so prohibitive and the options were varied. This investigation aimed at evaluating effectiveness, safety, and cost-effectiveness for immuno-chemotherapy as a first-line therapeutic option for ES-SCLC patients.Multiple scientific literature repositories were searched for clinical studies where immuno-chemotherapy was regarded as the first-line treatment for ES-SCLC, which were published in English between Jan 1, 2000, and Nov 30, 2021. This study conducted a network meta-analysis (NMA) and cost-effectiveness analysis (CEA) based upon US-resident payer perspectives. Overall survival (OS), progression-free survival (PFS), and adverse events (AEs) were evaluated through NMA. In addition, costings, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-benefit ratio (ICER) were estimated by CEA.We identified 200 relevant search records, of which four randomized controlled trials (RCTs) (2,793 patients) were included. NMA demonstrated that the effect of atezolizumab plus chemotherapy was ranked at a more elevated position in comparison to other immuno-chemotherapy options and chemotherapy alone, within the general population. The influence of atezolizumab plus chemotherapy and durvalumab plus chemotherapy was ranked higher within populations experiencing non-brain metastases (NBMs) andbrain metastases (BMs), respectively. The CEA revealed that the ICERs of immuno-chemotherapy over chemotherapyalone were higher than the willingness-to-pay (WTP) threshold of $150,000/QALY in any population. However, treatment with atezolizumab plus chemotherapy and durvalumab plus chemotherapy were more favorable health advantages than other immuno-chemotherapy regimens and chemotherapy alone, and the results were 1.02 QALYs and 0.89 QALYs within overall populations and populations with BMs, respectively.The NMA and cost-effectiveness investigation demonstrated that atezolizumab plus chemotherapy could be an optimal first-line therapeutic option for ES-SCLC when compared with other immuno-chemotherapy regimens. Durvalumab plus chemotherapy is likely to be the most favorable first-line therapeutic option for ES-SCLC with BMs." @default.
• W4327603911 created "2023-03-17" @default.
• W4327603911 creator A5013197248 @default.
• W4327603911 creator A5019483797 @default.
• W4327603911 creator A5050501022 @default.
• W4327603911 creator A5056801551 @default.
• W4327603911 creator A5090738359 @default.
• W4327603911 date "2023-03-16" @default.
• W4327603911 modified "2023-09-25" @default.
• W4327603911 title "First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis" @default.
• W4327603911 cites W1966999467 @default.
• W4327603911 cites W1983856905 @default.
• W4327603911 cites W1990676527 @default.
• W4327603911 cites W2005295931 @default.
• W4327603911 cites W2049034349 @default.
• W4327603911 cites W2058264985 @default.
• W4327603911 cites W2068411642 @default.
• W4327603911 cites W2079315541 @default.
• W4327603911 cites W2123091553 @default.
• W4327603911 cites W2126499930 @default.
• W4327603911 cites W2130320283 @default.
• W4327603911 cites W2133104890 @default.
• W4327603911 cites W2260064945 @default.
• W4327603911 cites W2421496331 @default.
• W4327603911 cites W2480201404 @default.
• W4327603911 cites W2591303584 @default.
• W4327603911 cites W2595863515 @default.
• W4327603911 cites W2783091042 @default.
• W4327603911 cites W2888569999 @default.
• W4327603911 cites W2893960509 @default.
• W4327603911 cites W2908902360 @default.
• W4327603911 cites W2912536255 @default.
• W4327603911 cites W2915456024 @default.
• W4327603911 cites W2951235875 @default.
• W4327603911 cites W2959432976 @default.
• W4327603911 cites W2978795816 @default.
• W4327603911 cites W2982126618 @default.
• W4327603911 cites W3029013041 @default.
• W4327603911 cites W3030178583 @default.
• W4327603911 cites W3084064036 @default.
• W4327603911 cites W3110002524 @default.
• W4327603911 cites W3118711697 @default.
• W4327603911 cites W3119005666 @default.
• W4327603911 cites W3173550514 @default.
• W4327603911 cites W3178712649 @default.
• W4327603911 cites W3188488521 @default.
• W4327603911 doi "https://doi.org/10.3389/fpubh.2023.1028202" @default.
• W4327603911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37006537" @default.
• W4327603911 hasPublicationYear "2023" @default.
• W4327603911 type Work @default.
• W4327603911 citedByCount "1" @default.
• W4327603911 countsByYear W43276039112023 @default.
• W4327603911 crossrefType "journal-article" @default.
• W4327603911 hasAuthorship W4327603911A5013197248 @default.
• W4327603911 hasAuthorship W4327603911A5019483797 @default.
• W4327603911 hasAuthorship W4327603911A5050501022 @default.
• W4327603911 hasAuthorship W4327603911A5056801551 @default.
• W4327603911 hasAuthorship W4327603911A5090738359 @default.
• W4327603911 hasBestOaLocation W43276039111 @default.
• W4327603911 hasConcept C121608353 @default.
• W4327603911 hasConcept C126322002 @default.
• W4327603911 hasConcept C143998085 @default.
• W4327603911 hasConcept C168563851 @default.
• W4327603911 hasConcept C177713679 @default.
• W4327603911 hasConcept C2775949291 @default.
• W4327603911 hasConcept C2776256026 @default.
• W4327603911 hasConcept C2776694085 @default.
• W4327603911 hasConcept C2777701055 @default.
• W4327603911 hasConcept C2777742743 @default.
• W4327603911 hasConcept C2780057760 @default.
• W4327603911 hasConcept C2908647359 @default.
• W4327603911 hasConcept C535046627 @default.
• W4327603911 hasConcept C71924100 @default.
• W4327603911 hasConcept C95190672 @default.
• W4327603911 hasConcept C99454951 @default.
• W4327603911 hasConceptScore W4327603911C121608353 @default.
• W4327603911 hasConceptScore W4327603911C126322002 @default.
• W4327603911 hasConceptScore W4327603911C143998085 @default.
• W4327603911 hasConceptScore W4327603911C168563851 @default.
• W4327603911 hasConceptScore W4327603911C177713679 @default.
• W4327603911 hasConceptScore W4327603911C2775949291 @default.
• W4327603911 hasConceptScore W4327603911C2776256026 @default.
• W4327603911 hasConceptScore W4327603911C2776694085 @default.
• W4327603911 hasConceptScore W4327603911C2777701055 @default.
• W4327603911 hasConceptScore W4327603911C2777742743 @default.
• W4327603911 hasConceptScore W4327603911C2780057760 @default.
• W4327603911 hasConceptScore W4327603911C2908647359 @default.
• W4327603911 hasConceptScore W4327603911C535046627 @default.
• W4327603911 hasConceptScore W4327603911C71924100 @default.
• W4327603911 hasConceptScore W4327603911C95190672 @default.
• W4327603911 hasConceptScore W4327603911C99454951 @default.
• W4327603911 hasLocation W43276039111 @default.
• W4327603911 hasLocation W43276039112 @default.
• W4327603911 hasLocation W43276039113 @default.
• W4327603911 hasOpenAccess W4327603911 @default.
• W4327603911 hasPrimaryLocation W43276039111 @default.
• W4327603911 hasRelatedWork W2767478109 @default.
• W4327603911 hasRelatedWork W2968490685 @default.
• W4327603911 hasRelatedWork W3083344515 @default.
• W4327603911 hasRelatedWork W3107468528 @default.

• next